Expert Pitch

Suspending AstraZeneca vaccine risks more blood clots, not less

Cornell University
16-Mar-2021 1:55 PM EDT, by Cornell University

A number of European countries have suspended use of AstraZeneca’s COVID-19 vaccine over reports of dangerous blood clots in some recipients, though the company and international regulators say there is no evidence the shot is to blame.

Luis Schang is a molecular virologist who studies the interactions between viruses and cells, interactions which determine the outcomes of the infection and, consequently, pathogenicity. He says despite the concerns, this is likely the most careful worldwide vaccination campaign ever performed, and that suspending AstraZeneca vaccinations may lead to more blood clots — a common side effect of severe COVID-19.

Schang says:

“A number of countries have suspended the use of the AstraZeneca vaccine out of an excess of caution after a very limited number of consequential blood clots (deep vein thrombosis –DVT – and pulmonary embolism) were reported in some vaccinated patients. Through March 8 in the EU and the UK, 37 total cases were reported to AstraZeneca among 17 million vaccines, which is below the expected normal incidence of this types of thrombosis in the populations being vaccinated.

“The UK has applied 26.06 million doses of this vaccine to date without any reported increase in the frequency of these types of blood clots. The WHO and European Medicine Agencies (EMA), the EU regulatory agency, are meeting this week to perform an in-depth analysis of the reported cases, but in the meantime they both have expressed that they have found no evidence that the events were caused by the vaccine. 

“As a major concern, suspending vaccinations may result in an increase in total thrombosis cases. Thrombosis is common in serious COVID-19 cases, which is far more frequent in the susceptible populations being vaccinated than the reported frequency of blood clots among the vaccinated.

“The fact that this low frequency of a rare event was detected and reported and is being so thoroughly followed up constitutes an even further re-assurance that the SARS CoV-2/COVID-19 vaccination campaigns are proceeding with extreme caution and attention to even the most remote possibility of negative side effects. This may well be the most careful worldwide vaccination campaign ever performed.”

 

- 30 -

 

 




Filters close

Showing results

110 of 5429
Released: 16-Apr-2021 4:10 PM EDT
Rutgers Expert Addresses Questions on COVID-19 Vaccine Rollout and Variant Issues
Rutgers University-New Brunswick

Stanley H. Weiss, an epidemiologist in infectious and chronic diseases, and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health, talks about vaccine side effects, the hesitancy that still exists and why it is important to get vaccinated when it’s your turn.

Released: 16-Apr-2021 3:15 PM EDT
Studies suggest people with blood cancers may not be optimally protected after COVID-19 vaccination
American Society of Hematology (ASH)

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

Newswise: Simulations reveal how dominant SARS-CoV-2 strain binds to host, succumbs to antibodies
Released: 16-Apr-2021 2:35 PM EDT
Simulations reveal how dominant SARS-CoV-2 strain binds to host, succumbs to antibodies
Los Alamos National Laboratory

Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.

Newswise: 262279_web.jpg
Released: 16-Apr-2021 2:15 PM EDT
Experimental antiviral for COVID-19 effective in hamster study
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.

Newswise:Video Embedded forum-tackles-vaccine-hesitancy-in-the-black-community
VIDEO
Released: 16-Apr-2021 1:25 PM EDT
Forum Tackles Vaccine Hesitancy in the Black Community
Cedars-Sinai

Leading healthcare and faith leaders addressed key issues that are contributing to vaccine hesitancy in Black communities during a national online discussion this week, explaining that a lack of access to healthcare, concerns over vaccine safety, and religious beliefs are keeping many from getting COVID-19 vaccines.

Newswise: COVID-19: Scientists identify human genes that fight infection
Released: 16-Apr-2021 1:10 PM EDT
COVID-19: Scientists identify human genes that fight infection
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys have identified a set of human genes that fight SARS-CoV-2 infection, the virus that causes COVID-19. Knowing which genes help control viral infection can greatly assist researchers’ understanding of factors that affect disease severity and also suggest possible therapeutic options. The genes in question are related to interferons, the body’s frontline virus fighters.

Newswise: Study of More Than 3,000 Members of the US Marine Corps. Reveals Past COVID-19 Infection Does Not Fully Protect Young People Against Reinfection
Released: 16-Apr-2021 11:35 AM EDT
Study of More Than 3,000 Members of the US Marine Corps. Reveals Past COVID-19 Infection Does Not Fully Protect Young People Against Reinfection
Mount Sinai Health System

Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.

Released: 15-Apr-2021 8:45 PM EDT
Beyond Boundaries: R Adams Cowley Shock Trauma Center Celebrates Heroes
University of Maryland Medical Center

More than 65 first responders and top trauma medicine professionals who saved the lives of two critically ill patients were honored tonight at the 31st annual R Adams Cowley Shock Trauma Celebration of Heroes. Funds raised by the virtual event will support the Center for Critical Care and Trauma Education.

Released: 15-Apr-2021 4:10 PM EDT
Penn Study Suggests Those Who Had COVID-19 May Only Need One Vaccine Dose
Perelman School of Medicine at the University of Pennsylvania

New findings from Penn suggest that people who have recovered from COVID-19 may only need a single mRNA vaccine dose. However, those who did not have COVID-19 did not have a full immune response until after a second vaccine dose, reinforcing the importance of completing the two recommended doses.


Showing results

110 of 5429

close
1.5522